Heather J Landau

List of Publications by Year
in descending order

101	3,618	186265 28	138484 58
papers	citations	h-index	g-index

104	104	104	3930
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	7.2	29
2	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 1-7.	3.0	42
3	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation, 2022, 57, 295-298.	2.4	2
4	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer Journal, 2022, 12, 27.	6.2	19
5	Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 1095-1100.	2.4	4
6	Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma. Leukemia and Lymphoma, 2022, 63, 2233-2237.	1.3	3
7	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995.	5.2	5
8	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2160-2166.	7.0	2
9	Involved free light chains <10â€‰mg/L with treatment predict better outcomes in systemic lightâ€chain amyloidosis. American Journal of Hematology, 2021, 96, E20-E23.	4.1	4
10	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	4.1	15
11	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood, 2021, 137, 1527-1537.	1.4	42
12	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Clinical Cancer Research, 2021, 27, 2111-2118.	7.0	5
13	Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 939-944.	3.7	2
14	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€weekly carfilzomib (45 and 56â€‰mg/m‹sup›2‹/sup›) in combination with lenalidomide and dexamethasone. American Journal of Hematology, 2021, 96, E193-E196.	4.1	10
15	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. Transplantation and Cellular Therapy, 2021, 27, 438.e1-438.e6.	1.2	11
16	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2021, 8, e422-e432.	4.6	50
17	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2021, 7, 862.	7.1	63
18	Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. Blood, 2021, 138, 3271-3271.	1.4	1

#	Article	IF	Citations
19	Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. Blood, 2021, 138, 1644-1644.	1.4	7
20	AL amyloidosis: untangling new therapies. Hematology American Society of Hematology Education Program, 2021, 2021, 682-688.	2.5	8
21	Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. Biology of Blood and Marrow Transplantation, 2020, 26, 204-208.	2.0	10
22	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 58-65.	2.0	8
23	Kidney transplantation in AL Amyloidosis: is it time to maximize access?. British Journal of Haematology, 2020, 188, e1-e4.	2.5	11
24	Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 198-200.	0.4	17
25	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, 3617.	12.8	41
26	Jettison-MS of Nucleic Acid Species. Journal of the American Society for Mass Spectrometry, 2020, 31, 1641-1646.	2.8	2
27	Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2040-2046.	2.0	1
28	Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis. JACC: CardioOncology, 2020, 2, 223-231.	4.0	27
29	Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e135-e137.	2.0	10
30	Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. Journal of Clinical Oncology, 2020, 38, 1455-1462.	1.6	31
31	Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e137-e143.	0.4	12
32	A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study. Leukemia and Lymphoma, 2020, 61, 488-490.	1.3	0
33	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1394-1401.	2.0	8
34	Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. Journal of Clinical Investigation, 2020, 130, 733-747.	8.2	161
35	A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808). Blood, 2020, 136, 20-21.	1.4	16
36	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	1.4	0

#	Article	IF	Citations
37	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). Blood, 2020, 136, 8-10.	1.4	0
38	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. Blood, 2020, 136, 37-38.	1.4	1
39	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 7-7.	1.4	1
40	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Blood, 2020, 136, 50-51.	1.4	0
41	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response. Blood, 2020, 136, 21-23.	1.4	1
42	Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1125, 121711.	2.3	9
43	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. Journal of Clinical Oncology, 2019, 37, 589-597.	1.6	184
44	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal, 2019, 9, 101.	6.2	40
45	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
46	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood, 2019, 134, 139-139.	1.4	34
47	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, 2019, 134, 3166-3166.	1.4	27
48	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 862-862.	1.4	34
49	First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis. Blood, 2019, 134, 5452-5452.	1.4	5
50	Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 1379-1385.	2.0	19
51	Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of Blood and Marrow Transplantation, 2018, 24, 871-876.	2.0	35
52	Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia and Lymphoma, 2018, 59, 1981-1985.	1.3	16
53	Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clinical Biochemistry, 2018, 51, 66-71.	1.9	49
54	Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic CellÂTransplantation. Journal of the American Society of Echocardiography, 2018, 31, 64-70.	2.8	41

#	Article	IF	Citations
55	Managing multiple myeloma in elderly patients. Leukemia and Lymphoma, 2018, 59, 1300-1311.	1.3	18
56	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	3.0	20
57	Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis. Haematologica, 2018, 103, e610-e612.	3.5	11
58	Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2018, 24, 1823-1827.	2.0	12
59	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leukemia Research, 2018, 74, 130-136.	0.8	47
60	Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. Blood, 2018, 132, 608-608.	1.4	9
61	Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. Blood, 2018, 132, 959-959.	1.4	71
62	Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers. Blood, 2018, 132, 2258-2258.	1.4	2
63	Genomic Landscape of Multiple Myeloma with Elevated Lactate Dehydrogenase. Blood, 2018, 132, 470-470.	1.4	0
64	Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia and Lymphoma, 2017, 58, 1823-1831.	1.3	57
65	Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia and Lymphoma, 2017, 58, 2962-2965.	1.3	4
66	Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia and Lymphoma, 2017, 58, 1757-1759.	1.3	7
67	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	4.6	132
68	Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency*. Leukemia and Lymphoma, 2017, 58, 1123-1129.	1.3	11
69	SP051NEOD001 DEMONSTRATES RENAL BIOMARKER RESPONSES IN A PHASE 1/2 STUDY IN PATIENTS WITH IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT RENAL DYSFUNCTION. Nephrology Dialysis Transplantation, 2016, 31, i103-i103.	0.7	0
70	Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood, 2016, 127, 2355-2356.	1.4	13
71	Organ response in patients with AL amyloidosis treated with NEOD001, an amyloidâ€directed monoclonal antibody. American Journal of Hematology, 2016, 91, E506-E508.	4.1	26
72	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology, 2016, 34, 1097-1103.	1.6	176

#	Article	IF	Citations
73	CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 258-267.	2.0	21
74	NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study. Blood, 2016, 128, 644-644.	1.4	9
75	Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 645-645.	1.4	46
76	Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution. Blood, 2016, 128, 2090-2090.	1.4	0
77	Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Advances in Therapy, 2015, 32, 920-928.	2.9	187
78	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749.	1.6	163
79	Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 468-472.	2.0	29
80	Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 1785-1785.	1.4	4
81	Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2015, 126, 3041-3041.	1.4	2
82	Induction with Bortezomib and Dexamethasone (BD) Followed By Risk Adapted High Dose Melphalan and Autologous Stem Cell Transplantation and BD Consolidation in Patients with AL Amyloidosis: A Phase II Feasibility Study. Blood, 2015, 126, 3178-3178.	1.4	1
83	Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy. Blood, 2015, 126, 4257-4257.	1.4	8
84	Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials. Blood, 2015, 126, 1975-1975.	1.4	0
85	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. Blood, 2015, 126, 3049-3049.	1.4	0
86	Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014. Hematology/Oncology Clinics of North America, 2014, 28, 815-827.	2.2	2
87	Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1796-1803.	2.0	73
88	A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood, 2014, 124, 899-906.	1.4	73
89	Upfront Plerixafor Plus G-CSF Versus Cyclophosphamide Plus G-CSF for Autologous Stem Cell Mobilization in Multiple Myeloma Patients: An Update on Cost Analysis Study at Memorial Sloan Kettering Cancer Center. Blood, 2014, 124, 848-848.	1.4	1
90	Salvage Second Hematopoietic Cell Transplantation inÂMyeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 760-766.	2.0	98

#	Article	IF	Citations
91	Multiple Copies of MLL Is The Most Commonly Detected Cytogenetic Abnormality In Newly Diagnosed Multiple Myeloma and May Modify Disease Risk. Blood, 2013, 122, 1910-1910.	1.4	2
92	Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma. Blood, 2013, 122, 3329-3329.	1.4	1
93	Pilot Study To Evaluate The Prevalence Of Actionable Oncogenic Mutations In Patients With Relapsed Refractory Multiple Myeloma. Blood, 2013, 122, 755-755.	1.4	1
94	T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation For Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics Permits Long-Lasting Remissions In The Absence Of Graft-Versus-Host Disease. Blood, 2013, 122, 2115-2115.	1.4	0
95	The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells. Molecular Cancer Therapeutics, 2012, 11, 1781-1788.	4.1	52
96	Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leukemia and Lymphoma, 2012, 53, 275-281.	1.3	13
97	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1770-1781.	27.0	1,024
98	Treatment of Heparin-Induced Thrombocytopenia and Associated Thromboses with Fondaparinux.. Blood, 2009, 114, 2096-2096.	1.4	1
99	Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.. Blood, 2008, 112, 3329-3329.	1.4	2
100	High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.. Blood, 2007, 110, 5113-5113.	1.4	0
101	Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leukemia and Lymphoma, 0, , 1-10.	1.3	1